Volume | 34,364 |
|
|||||
News | - | ||||||
Day High | 1.5797 | Low High |
|||||
Day Low | 1.49 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sonnet BioTherapeutics Holdings Inc | SONN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.53 | 1.49 | 1.5797 | 1.57 | 1.4999 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
302 | 34,364 | $ 1.54 | $ 52,793 | - | 1.08 - 36.96 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:44:45 | formt | 450 | $ 1.58 | USD |
Sonnet BioTherapeutics Holdings Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.75M | 1.75M | - | 350k | -29.72M | -16.98 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sonnet BioTherapeutics News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SONN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.50 | 1.6992 | 1.3202 | 1.51 | 93,473 | 0.08 | 5.33% |
1 Month | 1.42 | 1.6992 | 1.18 | 1.42 | 71,848 | 0.16 | 11.27% |
3 Months | 3.80 | 3.80 | 1.08 | 1.74 | 71,129 | -2.22 | -58.42% |
6 Months | 9.90 | 26.40 | 1.08 | 12.09 | 1,368,831 | -8.32 | -84.04% |
1 Year | 21.78 | 36.96 | 1.08 | 11.27 | 1,565,976 | -20.20 | -92.75% |
3 Years | 791.56 | 1,051.82 | 1.08 | 177.61 | 3,033,239 | -789.98 | -99.8% |
5 Years | 1,915.76 | 4,989.60 | 1.08 | 330.70 | 2,870,699 | -1,914.18 | -99.92% |
Sonnet BioTherapeutics Description
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. |